Clinical Trial Update: Lazertinib 160mg in EGFR T790M NSCLC [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for lazertinib 160mg in EGFR T790M non-small cell lung cancer (Stage IV).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Cancer
• Non-small Cell Lung Cancer

Drugs mentioned

• Lazertinib (lazertinib)

Snippet

Sponsor: Samsung Medical Center | Conditions: Lung Cancer Stage IV, EGFR T790M | Phase 2 | Status: UNKNOWN